Company intelligence / Profile preview
Aerami Therapeutics
Durham, North Carolina, United Statesaerami.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Aerami Therapeutics has completed Phase 1 clinical trials for AER-901 (inhaled imatinib) and plans to advance it to Phase 2 for PAH and PH-ILD. The company has also developed the AFINA inhaler platform.
- Therapeutic areas
- PulmonologyCardiovascularEndocrinology
- Modalities
- Inhaled therapiessmall molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Hangzhou Chance Pharmaceuticals (exclusive license for AER-901 in Greater China)Vectura Limited (license for FOX device)
Beyond the preview
Go deeper on Aerami Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aerami Therapeutics.